T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
Understanding the immune response to SARS-CoV-2 is dependent on being able to distinguish COVID-19 immune responses from cross-reactive immune responses to other coronaviruses. Here the authors show that choice of antigens and whether an ICS, ELISPOT or T cell proliferation assay is used has a major...
Enregistré dans:
Documents similaires
-
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
par: Donal T. Skelly, et autres
Publié: (2021) -
A lipid-rich gestational diet predisposes offspring to nonalcoholic fatty liver disease: a potential sequence of events
par: Hughes AN, et autres
Publié: (2014) -
Analysis of temporal trends in potential COVID-19 cases reported through NHS Pathways England
par: Quentin J. Leclerc, et autres
Publié: (2021) -
Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells
par: The International Stem Cell Initiative
Publié: (2018) -
COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
par: Carl A B Pearson, et autres
Publié: (2021)